These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 15849466)

  • 41. Vitamin B6 resistant primary hyperoxaluria type I. Report of 5 cases.
    Streefland M; Donckerwolcke RA
    Helv Paediatr Acta; 1989 Feb; 43(4):313-24. PubMed ID: 2708072
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Pyridoxine-responsive PH1: treatment.
    Toussaint C
    J Nephrol; 1998; 11 Suppl 1():49-50. PubMed ID: 9604811
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Early and unusual presentation of type I primary hyperoxaluria.
    Giugliani R; Jardim L; Edelweiss MI; Rosa A
    Child Nephrol Urol; 1990; 10(2):107-8. PubMed ID: 2253247
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Pharmacological approaches in the treatment of primary hyperoxaluria.
    Holmes RP
    J Nephrol; 1998; 11 Suppl 1():32-5. PubMed ID: 9604807
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Clinical implications of mutation analysis in primary hyperoxaluria type 1.
    van Woerden CS; Groothoff JW; Wijburg FA; Annink C; Wanders RJ; Waterham HR
    Kidney Int; 2004 Aug; 66(2):746-52. PubMed ID: 15253729
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Metabolism of pyridoxine in mild metabolic hyperoxaluria and primary hyperoxaluria (type 1).
    Edwards P; Rose GA
    Urol Int; 1991; 47(3):113-7. PubMed ID: 1771698
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Transplantation procedures in primary hyperoxaluria type 1.
    Latta A; Müller-Wiefel DE; Sturm E; Kemper M; Burdelski M; Broelsch CE
    Clin Nephrol; 1996 Jul; 46(1):21-3. PubMed ID: 8832145
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Hyperoxaluria type I: therapeutic effects of pyridoxine hydrochloride and inheritance patterns of the disease in a family.
    Yano S; Yoshino M; Nishiyori A; Nakao M; Matsumoto T; Ito Y; Yamashita F; Shimada A; Inokuchi T
    Kurume Med J; 1988; 35(3):127-33. PubMed ID: 3236825
    [No Abstract]   [Full Text] [Related]  

  • 49. Overexpression of human alanine:glyoxylate aminotransferase in Escherichia coli: renaturation from guanidine-HCl and affinity for pyridoxal phosphate co-factor.
    Coulter-Mackie MB; Lian Q; Wong SG
    Protein Expr Purif; 2005 May; 41(1):18-26. PubMed ID: 15802217
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Primary hyperoxaluria type III gene HOGA1 (formerly DHDPSL) as a possible risk factor for idiopathic calcium oxalate urolithiasis.
    Monico CG; Rossetti S; Belostotsky R; Cogal AG; Herges RM; Seide BM; Olson JB; Bergstrahl EJ; Williams HJ; Haley WE; Frishberg Y; Milliner DS
    Clin J Am Soc Nephrol; 2011 Sep; 6(9):2289-95. PubMed ID: 21896830
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Glycolate oxidase deficiency in a patient with congenital hyperinsulinism and unexplained hyperoxaluria.
    Clifford-Mobley O; Rumsby G; Kanodia S; Didi M; Holt R; Senniappan S
    Pediatr Nephrol; 2017 Nov; 32(11):2159-2163. PubMed ID: 28752386
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Data from a large European study indicate that the outcome of primary hyperoxaluria type 1 correlates with the AGXT mutation type.
    Mandrile G; van Woerden CS; Berchialla P; Beck BB; Acquaviva Bourdain C; Hulton SA; Rumsby G;
    Kidney Int; 2014 Dec; 86(6):1197-204. PubMed ID: 24988064
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Primary hyperoxaluria: effect of treatment with vitamin B6 and shock waves.
    Amato M; Donzelli S; Lombardi M; Salvadori M; Carini M; Selli C; Caudarella R
    Contrib Nephrol; 1987; 58():190-2. PubMed ID: 3691125
    [No Abstract]   [Full Text] [Related]  

  • 54. Late-onset primary hyperoxaluria triggered by hypothyroidism and presenting as rapidly progressive renal failure--description of a new mutation.
    Tintillier M; Pochet JM; Cosyns JP; Delgrange E; Donckier J
    Clin Nephrol; 2004 Aug; 62(2):155-7. PubMed ID: 15356974
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Vitamin B6 in primary hyperoxaluria I: first prospective trial after 40 years of practice.
    Hoyer-Kuhn H; Kohbrok S; Volland R; Franklin J; Hero B; Beck BB; Hoppe B
    Clin J Am Soc Nephrol; 2014 Mar; 9(3):468-77. PubMed ID: 24385516
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Glycolate Oxidase Is a Safe and Efficient Target for Substrate Reduction Therapy in a Mouse Model of Primary Hyperoxaluria Type I.
    Martin-Higueras C; Luis-Lima S; Salido E
    Mol Ther; 2016 Apr; 24(4):719-25. PubMed ID: 26689264
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Results of treatment with oral citrate and pyridoxine in patients with primary hyperoxaluria type 1].
    Castelló Girona F; Riudor Taravilla E; Enríquez Civicos G; Güell Torné C; Fornaguera Soler F
    An Esp Pediatr; 1999 Apr; 50(4):397-401. PubMed ID: 10356835
    [No Abstract]   [Full Text] [Related]  

  • 58. Primary hyperoxaluria type 1: An underestimated cause of nephrocalcinosis and chronic renal failure in Saudi Arabian children.
    Sanjad SA; Al-Abbad A; Al-Sabban E
    Ann Saudi Med; 1999; 19(1):4-7. PubMed ID: 17337975
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Structural and functional insights on the roles of molecular chaperones in the mistargeting and aggregation phenotypes associated with primary hyperoxaluria type I.
    Fernández-Higuero JÁ; Betancor-Fernández I; Mesa-Torres N; Muga A; Salido E; Pey AL
    Adv Protein Chem Struct Biol; 2019; 114():119-152. PubMed ID: 30635080
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Phenotype-Genotype Correlations and Estimated Carrier Frequencies of Primary Hyperoxaluria.
    Hopp K; Cogal AG; Bergstralh EJ; Seide BM; Olson JB; Meek AM; Lieske JC; Milliner DS; Harris PC;
    J Am Soc Nephrol; 2015 Oct; 26(10):2559-70. PubMed ID: 25644115
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.